Intellia rapporterar starka fas iii-resultat för hae-behandling

12 maj 2026

Rapporterad av AI

Intellia Therapeutics presenterade huvudresultat från sin fas III-studie HALO gällande HAE under Bank of America Global Healthcare Conference den 12 maj. Resultaten visade på betydande kliniska fördelar för patienter med tillståndet.

Finansdirektör Edward Dulac beskrev resultaten som mycket uppmuntrande under sessionen. Alla patienter uppnådde en meningsfull klinisk nytta, där 62 procent förblev anfallsfria och terapifria vid slutet av den 28 veckor långa primära observationsperioden. Minskningen av anfallsfrekvensen nådde det höga 80-procentsintervallet, resultat som enligt Dulac matchar eller överträffar tidigare rapporter inom området.

Relaterade artiklar

A doctor giving an injection to a patient in a clinic with brain scans in the background, illustrating a trial on immune drug for depression.

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

28 maj 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.

World ALS Day highlights advances in treatments

This Sunday marks World ALS Day with emphasis on new genetic treatments that have stabilized or restored motor functions in some patients.

Syntara reports positive FDA feedback on amsulostat trial

30 april 2026 Rapporterad av AI

Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.

Health

Abatacept delays rheumatoid arthritis for years after treatment

Health

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Business

UnitedHealth reports strong first quarter at healthcare conference

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

Pulse Biosciences presents ablation technology at healthcare conference

14 maj 2026 Rapporterad av AI

Pulse Biosciences outlined its progress with nanosecond pulsed field ablation technology during a presentation at the Bank of America Global Healthcare Conference on May 13.

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

AI identifies breast cancer drug for multiple viruses

3 april 2026 Rapporterad av AI

A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.

18 juni 2026 16:29

Intellia rapporterar starka fas iii-resultat för hae-behandling

Relaterade artiklar

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

World ALS Day highlights advances in treatments

Syntara reports positive FDA feedback on amsulostat trial

Abatacept delays rheumatoid arthritis for years after treatment

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

UnitedHealth reports strong first quarter at healthcare conference

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

Pulse Biosciences presents ablation technology at healthcare conference

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

AI identifies breast cancer drug for multiple viruses

Oncolys president reflects on journey to world-first cancer treatment

Oral GLP-1 pill shows strong results in diabetes trial

Longevity startup doses first patient in vision loss trial

Clínica Medilaser strengthens brain tumor care in Huila

Demis Hassabis spotlights ai for cancer research at google io

Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Caribou Biosciences presents car-t updates at healthcare conference

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Astrana Health CEO reports strong Q1 results at conference

Scientists call for multi-pronged strategies against Alzheimer's

Denna webbplats använder cookies